Daclizumab is a humanized immunoglobulin G1 (IgG1) mAb that reversibly binds the so-called Tac epitope (binding site for IL-2) on the α-subunit (CD25) of the high-affinity IL-2 receptor (IL-2R-HA), which is highly expressed on activated T lymphocytes and regulatory T (Tregs) cells ...